12399456https://www.upal.com.my/zh/feeds/jobFeedKwongwahArray ( [0] => HTTP/1.1 200 OK [1] => Date: Fri, 04 Apr 2025 07:29:36 GMT [2] => Content-Type: text/xml; charset=utf-8 [3] => Connection: close [4] => Server: cloudflare [5] => Nel: {"success_fraction":0,"report_to":"cf-nel","max_age":604800} [6] => Vary: Accept-Encoding [7] => X-Powered-By: PHP/7.4.33 [8] => Cache-Control: no-cache, private [9] => Cf-Ray: 92af1876f8af69c8-LAX [10] => X-Frame-Options: SAMEORIGIN [11] => X-Xss-Protection: 1; mode=block [12] => X-Content-Type-Options: nosniff [13] => Referrer-Policy: no-referrer-when-downgrade [14] => Cf-Cache-Status: DYNAMIC [15] => Report-To: {"endpoints":[{"url":"https:\/\/a.nel.cloudflare.com\/report\/v4?s=gDJNn5I%2B%2BGhlAkmN9Ndiea0InBOiLVsEYhT6IBJj4nCyC9yIL9AkcQkF6aewoNVnR0Prqv9Jgipk05%2FvCHnl8KQG7oy1xHfFdstFZQs4kNghED8oK6efIoaDagOczNdmRZQ%3D"}],"group":"cf-nel","max_age":604800} [16] => Set-Cookie: UpalLiveSession=eyJpdiI6InVSbzNOVnZtYjRkWWNVVm9hSUtFNHc9PSIsInZhbHVlIjoiXC94YmdaaFZJOW9ybzE1Tkt3VVA3RDNWRlFBaVwvNXFFUVpja3BLZG1JbWVLREY3Q2ZhdUQ0dHVXRFhDRzFcL3hSYjFpc0U4SHlBQ0RGdWtMWWpzWDRnK3c9PSIsIm1hYyI6ImMwMGVhMjMwYmE4ZDVlOTQ5Y2E3MTNiNWY0MTBjNWI1ZDc5NDE3YjNiOTUyMDBmMGY0ZmY1MTVhY2RiOWE5NWUifQ%3D%3D; HttpOnly; Path=/; Max-Age=94608000; Expires=Mon, 03 Apr 2028 06:39:31 GMT [17] => alt-svc: h3=":443"; ma=86400 [18] => server-timing: cfL4;desc="?proto=TCP&rtt=183770&min_rtt=183704&rtt_var=38836&sent=5&recv=7&lost=0&retrans=0&sent_bytes=3001&recv_bytes=756&delivery_rate=15763&cwnd=33&unsent_bytes=0&cid=376d388a118072b3&ts=1012&x=0" ) 789

 

 

新冠肺炎疫情持续，目前检测病毒多以核酸检验方式进行，出结果需约4小时。台湾的中央研究院周日表示，成功合成能辨识新冠肺炎病毒的蛋白质单株抗体群，将用作检测快筛装置的关键试剂。若成功量产，最快15至20分钟有检测结果。

中研院基因体研究中心研究员杨安指，快筛的关键在于其抗体试剂需能准确辨识新冠肺炎病毒，针对7种人类冠状病毒核蛋白抗原，从第一批46株单株抗体中，发现有1株抗体只对新冠肺炎病毒有反应，不会与嚴重急性呼吸系統綜合症（SARS）、中东呼吸综合征（MERS）病毒等交叉反应，可快速辨识是否感染。

研究院上月初开始研究快速合成新冠肺炎病毒核蛋白抗原，中研院院长廖俊智表示，下阶段将联同台湾的经济部与数家厂商讨论试剂生产，希望在3到4个月内通过台湾的卫福部验证，并进行临床试验。

---

// // // //